BiotechTube

rondecabtagene autoleucel + axicabtagene ciloleucel + lisocabtagene maraleucel

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Large B-cell Lymphoma

Conditions

Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed

Trial Timeline

Jan 12, 2026 → Jan 1, 2032

NCT ID
NCT07188558

About rondecabtagene autoleucel + axicabtagene ciloleucel + lisocabtagene maraleucel

rondecabtagene autoleucel + axicabtagene ciloleucel + lisocabtagene maraleucel is a phase 3 stage product being developed by Lyell Immunopharma for Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07188558. Target conditions include Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma.

What happened to similar drugs?

1 of 20 similar drugs in Large B-cell Lymphoma were approved

Approved (1) Terminated (2) Active (17)
✅RAD001 + Paclitaxel + CarboplatinNovartisApproved
🔄Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3
🔄Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
🔄Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
🔄acalabrutinib + placebo + Prednisone + Rituximab + Cyclophosphamide + Vincristine + DoxorubicinAstraZenecaPhase 3
🔄AZD0486 + R-mini-CHOPAstraZenecaPhase 3
🔄R-miniCHOP + Acalabrutinib + R-miniCHOPAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07188558Phase 3Recruiting

Competing Products

20 competing products in Large B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
35
rituximabCelltrionPhase 1
21
YM155Astellas PharmaPhase 2
27
enzastaurin + gemcitabine + rituximab + oxaliplatinEli LillyPhase 2
35
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6Johnson & JohnsonPhase 2
31
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
35
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
42
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3
47
ABBV-525AbbViePhase 1
36
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + EpcoritamabAbbViePhase 1/2
36
Copanlisib + VenetoclaxAbbViePhase 1/2
36
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
44
Epcoritamab + LenalidomideAbbViePhase 2
39
Venetoclax + SelinexorAbbViePhase 1
29
EpcoritamabAbbViePhase 1
36
Loncastuximab Tesirine and EpcoritamabAbbViePhase 2
42
Epcoritamab + Epcoritamab, tafasitamab and lenalidomideAbbViePhase 2
42
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
44
bendamustine + navitoclax + rituximabAbbViePhase 2
27
EpcoritamabAbbViePhase 2
39